- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871362
Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol: A Pilot Study
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10369
- analyze & realize GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Caucasian males and females, 18-65 years of age
- Body mass index (BMI) 18.5-29.9 kg/m2
- Generally in good health, in particular an electrocardiogram (ECG) without pathological findings at screening
- High normal BP levels (130-139 / 85-89) for 20% of randomized subjects and hypertension grade 1 (140-159 / 90-99) BP levels for 80% of randomized subjects at screening (mean of the 2nd and 3rd measurement during the assessment in triplicate at screening) and at baseline (mean of the 2nd and 3rd measurement during the assessment in triplicate at week 0)
- LDL-C 100-159 mg/dL
Readiness to comply with study procedures, in particular:
- Consumption of the IP during the entire study
- Maintaining the habitual diet, with the exception of consumption of maximal 2 garlic cloves per week
- Accepting blood draws
- Complying with requirements for BP measurements (such as avoiding any strenuous exercise and stimulants (alcohol, caffeine) for at least 24 h before the measurement; refraining from extreme cold and heat exposure and food and fluid intake for at least 1 h before the measurement)
- Filling in health questionnaires
- Non-smoker / smoking cessation of last ≥12 months prior to screening
- Stable body weight in the last 3 months prior to screening (<3 kg self-reported change)
- If allowed concomitant medications are taken this must have been stable at least during the last month prior to screening
Women of child-bearing potential only:
- negative pregnancy testing (ß-HCG in urine at screening)
- commitment to use reliable contraception methods during the entire study Participation is based upon written informed consent form (ICF) by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.
Exclusion Criteria:
- Known sensitivity to any components of the IP
- Clinically significant disturbances in lipid metabolism
- Known genetic hyperlipidemia
- Known secondary hypertension
- Known white-coat hypertension
- Known type-1-diabetes
- Uncontrolled or within the last 6 months prior to screening diagnosed type-2-diabetes
- Untreated or non-stabilized thyroid disorder
History and/or presence of clinically significant cardiovascular disease as per investigator's judgement:
- Known congenital heart defects
- Myocardial infarction, heart failure, angina pectoris, life-threatening arrhythmia or stroke within the last 6 months prior to screening
- Existing thrombosis or disposition to thrombosis
Any other known significant or serious condition / disease that renders subjects ineligible, e.g.:
- History of malignancy within the past 5 years prior to screening
- Bleeding disorder and/or need for anticoagulants (anti-platelet agents are allowed)
- Current psychiatric care and/or use of neuroleptics
- Bariatric surgery in the last 12 months prior to screening
- Any known metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subject
- Known arm lymphedema (e.g. due to mastectomy)
- Other clinically relevant excursions of safety parameters and/or deviations > 2 x ULN (upper limit of normal)
Dietary habits that may interfere with the study objectives:
- Eating disorder
- Subjects with dietary restriction that may affect the study outcome
- Participation in a weight loss program
- Use of drugs or supplements that can influence SBP or DBP (e.g. ACE inhibitors, diuretics, calcium channel or ß-blockers, grape seed extract, coenzyme Q10 etc.) within the last 4 weeks prior to screening and during the study
- Use of lipid lowering drugs (affecting lipid metabolism, platelet function or antioxidant status, etc.) OR dietary or health supplements (e.g. omega-3 fatty acids, green tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as e.g. Becel), oat fiber, niacin, soy protein, psyllium seed husk, glucomannan, chitosan or probiotics/prebiotics) within the last 4 weeks prior to screening and during the study
- Use of drugs that can influence cholesterol levels (e.g. corticosteroids, amiodarone, estrogen, anabolic ster-oids)
- Use of weight loss treatment
- Use of any recreational drugs
- Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Women of child-bearing potential: pregnant or breast-feeding
- Participation in another study or blood donation during the last 30 days prior to screening
Any other reason deemed suitable for exclusion as per investigator's judgment, e.g.:
- Insufficient compliance with study procedures
- Inability to communicate with the site study staff
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IQP-AS-118
To be taken once daily with a glass of water.
The tablets should not be chewed, but swallowed whole.
|
Take one a day
|
Placebo Comparator: Placebo
To be taken once daily with a glass of water.
The tablets should not be chewed, but swallowed whole.
|
Take one a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure (Systolic & Diastolic)
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic blood pressure
Time Frame: 12 weeks
|
Week 4 and week 8 vs. week 0, respectively
|
12 weeks
|
Diastolic blood pressure
Time Frame: 12 weeks
|
Week 4 and week 8 vs. week 0, respectively
|
12 weeks
|
Fasting LDL-C concentration and non-HDL-C
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Fasting TC Concentration
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Fasting HDL-C Concentration
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Fasting TG Concentration
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Fasting LDL-C/HDL-C and TC/HDL-C ratio
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Fasting Lp (a) concentrations
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
hs-CRP
Time Frame: 12 weeks
|
Week 12 vs. Screening
|
12 weeks
|
Homocysteine
Time Frame: 12 weeks
|
Week 12 vs. Screening
|
12 weeks
|
Pulse wave assessment
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
Metabolome analysis
Time Frame: 12 weeks
|
Week 12 vs. week 0
|
12 weeks
|
SF-12
Time Frame: 12 weeks
|
Week 4, week 9 and week 12 vs.
week 0, respectively
|
12 weeks
|
Global evaluation of benefit by the subjects/ investigator
Time Frame: 12 weeks
|
Week 12 only
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ralf Uebelhack, MD, phD, analyze & realize GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- INQ/030915
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure
-
DongGuk UniversityActive, not recruitingHypertension | Blood Pressure | Ambulatory Blood Pressure | Home Blood Pressure MeasurementKorea, Republic of
-
University of JordanCompletedBlood Pressure | Heart Rate | Airway PressureJordan
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
Istituto Auxologico ItalianoCompletedArterial Hypertension | Ambulatory Blood Pressure Monitoring | Blood Pressure Determination | Home Blood Pressure MonitoringItaly
-
The Second Hospital of Shandong UniversityRecruitingBlood PressureChina
-
Heart Health Research CenterRecruiting
-
Swansea UniversityNational Taiwan Normal UniversityRecruitingBlood PressureTaiwan, United Kingdom
-
Columbia UniversityNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingBlood PressureUnited States
-
Yale UniversityPatient-Centered Outcomes Research InstituteRecruiting
Clinical Trials on IQP-AS-118
-
InQpharm GroupWithdrawn
-
InQpharm GroupWithdrawn
-
InQpharm GroupTerminatedCommon Cold | Upper Respiratory Tract InfectionsGermany
-
InQpharm GroupCompletedUpper Respiratory Tract SymptomsGermany
-
InQpharm GroupCompleted
-
InQpharm GroupCompleted
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID); ImQuest Pharmaceuticals...Completed
-
InQpharm GroupCompletedAppetite Regulation | Energy Intake | Appetite SuppressionGermany
-
Dow Pharmaceutical SciencesUnknownPlaque PsoriasisUnited States
-
InQpharm GroupCompletedHyperglycemia | PrediabetesGermany